GenSight Biologics S.A. (SIGHT.PA)
EUR 0.29
(-3.52%)
EUR 0.29
(-3.52%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -29.69 Million EUR | -12.78% |
| 2022 | -27.83 Million EUR | 1.03% |
| 2021 | -28.12 Million EUR | -12.8% |
| 2020 | -24.93 Million EUR | 17.7% |
| 2019 | -30.29 Million EUR | 8.31% |
| 2018 | -33.04 Million EUR | -37.74% |
| 2017 | -23.99 Million EUR | -8.95% |
| 2016 | -22.01 Million EUR | -61.18% |
| 2015 | -13.66 Million EUR | -102.59% |
| 2014 | -6.74 Million EUR | -137.57% |
| 2013 | -2.83 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -3.7 Million EUR | 41.26% |
| 2024 Q2 | -3.7 Million EUR | 0.0% |
| 2023 Q3 | -6.3 Million EUR | 65.49% |
| 2023 Q1 | -8.54 Million EUR | -8.26% |
| 2023 Q4 | -6.3 Million EUR | 0.0% |
| 2023 FY | -31.39 Million EUR | -12.78% |
| 2023 Q2 | -18.25 Million EUR | -113.64% |
| 2022 Q4 | -7.89 Million EUR | 0.0% |
| 2022 Q3 | -7.89 Million EUR | 40.37% |
| 2022 Q1 | -6.02 Million EUR | 43.72% |
| 2022 Q2 | -13.23 Million EUR | -119.81% |
| 2022 FY | -27.83 Million EUR | 1.03% |
| 2021 FY | -28.12 Million EUR | -12.8% |
| 2021 Q2 | -8.03 Million EUR | -139.0% |
| 2021 Q4 | -10.7 Million EUR | 0.0% |
| 2021 Q1 | -3.36 Million EUR | 71.48% |
| 2021 Q3 | -10.7 Million EUR | -33.21% |
| 2020 Q2 | -16.19 Million EUR | -137.87% |
| 2020 Q3 | -5.65 Million EUR | 65.05% |
| 2020 Q4 | -11.78 Million EUR | -108.27% |
| 2020 FY | -24.93 Million EUR | 17.7% |
| 2020 Q1 | -6.8 Million EUR | 54.25% |
| 2019 Q3 | -6.56 Million EUR | 66.54% |
| 2019 Q2 | -19.62 Million EUR | -128.72% |
| 2019 Q1 | -8.58 Million EUR | 64.33% |
| 2019 FY | -30.29 Million EUR | 8.31% |
| 2019 Q4 | -14.87 Million EUR | -126.56% |
| 2018 Q1 | -5.65 Million EUR | 18.69% |
| 2018 Q3 | -10.87 Million EUR | 18.45% |
| 2018 Q4 | -24.06 Million EUR | -121.33% |
| 2018 FY | -33.04 Million EUR | -37.74% |
| 2018 Q2 | -13.33 Million EUR | -135.85% |
| 2017 Q4 | -6.95 Million EUR | 0.0% |
| 2017 Q1 | -5.04 Million EUR | 20.55% |
| 2017 FY | -23.99 Million EUR | -8.95% |
| 2017 Q2 | -5.04 Million EUR | 0.0% |
| 2017 Q3 | -6.95 Million EUR | -37.82% |
| 2016 Q1 | -4.66 Million EUR | -49.77% |
| 2016 Q3 | -6.34 Million EUR | -36.23% |
| 2016 Q2 | -4.66 Million EUR | 0.0% |
| 2016 Q4 | -6.34 Million EUR | 0.0% |
| 2016 FY | -22.01 Million EUR | -61.18% |
| 2015 Q3 | -3.01 Million EUR | -29.89% |
| 2015 Q4 | -3.11 Million EUR | -3.32% |
| 2015 FY | -13.66 Million EUR | -102.59% |
| 2015 Q2 | -2.31 Million EUR | 0.0% |
| 2015 Q1 | -2.31 Million EUR | -8.82% |
| 2014 Q4 | -2.13 Million EUR | 0.0% |
| 2014 FY | -6.74 Million EUR | -137.57% |
| 2014 Q1 | -1.24 Million EUR | 0.0% |
| 2014 Q3 | -2.13 Million EUR | -71.73% |
| 2014 Q2 | -1.24 Million EUR | 0.0% |
| 2013 FY | -2.83 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -770.34% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 76.686% |
| Adocia SA | -17.62 Million EUR | -68.517% |
| Aelis Farma SA | -6.46 Million EUR | -359.619% |
| Biophytis S.A. | -14.33 Million EUR | -107.186% |
| Advicenne S.A. | -6.45 Million EUR | -359.904% |
| genOway Société anonyme | 2.06 Million EUR | 1537.857% |
| IntegraGen SA | -183.77 Thousand EUR | -16059.33% |
| Medesis Pharma S.A. | -4.22 Million EUR | -602.142% |
| Neovacs S.A. | -6.9 Million EUR | -329.906% |
| NFL Biosciences SA | -4.43 Million EUR | -570.275% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -3715.804% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -846.56% |
| Sensorion SA | -22.31 Million EUR | -33.102% |
| Theranexus Société Anonyme | -7.64 Million EUR | -288.504% |
| TME Pharma N.V. | -5.62 Million EUR | -428.023% |
| Valbiotis SA | -7.16 Million EUR | -314.749% |
| TheraVet SA | -2.17 Million EUR | -1265.265% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -46.372% |
| argenx SE | -417.15 Million EUR | 92.881% |
| BioSenic S.A. | -7.04 Million EUR | -321.818% |
| Celyad Oncology SA | -8.45 Million EUR | -251.141% |
| DBV Technologies S.A. | -85.24 Million EUR | 65.164% |
| Galapagos NV | -88.26 Million EUR | 66.355% |
| Genfit S.A. | -26.58 Million EUR | -11.723% |
| GeNeuro SA | -14.35 Million EUR | -106.836% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -85.681% |
| Innate Pharma S.A. | -12.66 Million EUR | -134.399% |
| Inventiva S.A. | -102.7 Million EUR | 71.087% |
| MaaT Pharma SA | -19.94 Million EUR | -48.904% |
| MedinCell S.A. | -20.97 Million EUR | -41.565% |
| Nanobiotix S.A. | -26.77 Million EUR | -10.893% |
| Onward Medical N.V. | -35.46 Million EUR | 16.262% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -552.775% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -29.192% |
| Oxurion NV | -12.11 Million EUR | -145.219% |
| Pharming Group N.V. | -4.87 Million EUR | -508.581% |
| Poxel S.A. | -28.76 Million EUR | -3.24% |
| Transgene SA | -30.01 Million EUR | 1.053% |
| Financière de Tubize SA | -2.14 Million EUR | -1285.091% |
| UCB SA | 604 Million EUR | 104.917% |
| Valneva SE | -82.08 Million EUR | 63.824% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | -2.979% |